Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease

American Journal of Pathology

Volumn 182, Issue 5, 2013, Pages 1659-1670

  Pennock, Steven ^a   Kim, David ^a   Mukai, Shizuo ^a   Kuhnle, Matthew ^b   Chun, Dal W ^b   Matsubara, Joanne ^c   Cui, Jing ^c   Ma, Patrick ^c   Maberley, David ^c   Samad, Arif ^d   Van Geest, Robert J ^e   Oberstein, Sarit L ^e   Schlingemann, Reinier O ^e   Kazlauskas, Andrius ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; RANIBIZUMAB; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EDEMA; FEMALE; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; VITREORETINOPATHY; VITREOUS BODY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BLINDNESS; CELL LINE; DISEASE SUSCEPTIBILITY; HUMANS; MICE; NEUTRALIZATION TESTS; PLATELET-DERIVED GROWTH FACTOR; PROTEIN MULTIMERIZATION; RABBITS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 84876694996     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.01.052     Document Type: Article

References (62)

1. Han D: Proliferative Vitreoretinopathy. In: Albert D, JW M, DT A, BA B editor. Philadelphia, PA: Elsevier Saunders; 2008;p. 2315-2324.
2. R.G. Michels, C.P. Wilkinson, and T.A. Rice Proliferative Retinopathy 1990 Mosby St. Louis pp 669-706
3. J.C. Pastor Proliferative vitreoretinopathy: an overview Surv Ophthalmol 43 1998 3 18
4. N.N. Patel, C. Bunce, R.H. Asaria, and D.G. Charteris Resources involved in managing retinal detachment complicated by proliferative vitreoretinopathy Retina 24 2004 883 887
5. R.H. Asaria, and D.G. Charteris Proliferative vitreoretinopathy: developments in pathogenesis and treatment Compr Ophthalmol Update 7 2006 179 185
6. R.H. Asaria, C.H. Kon, C. Bunce, C.S. Sethi, G.A. Limb, P.T. Khaw, G.W. Aylward, and D.G. Charteris Silicone oil concentrates fibrogenic growth factors in the retro-oil fluid Br J Ophthalmol 88 2004 1439 1442
7. P.A. Campochiaro Mechanisms in ophthalmic disease: pathogenic mechanisms in proliferative vitreoretinopathy Arch Ophthalmol 115 1997 237 241
8. B.M. Glaser, A. Cardin, and B. Biscoe Proliferative vitreoretinopathy: the mechanism of development of vitreoretinal traction Ophthalmology 94 1987 327 332
9. G.W. Abrams, S.P. Azen, B.W. McCuen 2nd, H.W. Flynn Jr., M.Y. Lai, and S.J. Ryan Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up: Silicone Study report 11 Arch Ophthalmol 115 1997 335 344
10. M.A. Bruhn, R.B. Pearson, R.D. Hannan, and K.E. Sheppard Second AKT: the rise of SGK in cancer signalling Growth Factors 28 2010 394 408
11. E.K. Kim, and E.J. Choi Pathological roles of MAPK signaling pathways in human diseases Biochim Biophys Acta 1802 2010 396 405
12. R.R. Koenen, and C. Weber Chemokines: established and novel targets in atherosclerosis EMBO Mol Med 3 2011 713 725
13. D. Raman, T. Sobolik-Delmaire, and A. Richmond Chemokines in health and disease Exp Cell Res 317 2011 575 589
14. A. Saggini, A. Anogeianaki, G. Maccauro, S. Tete, V. Salini, A. Caraffa, F. Conti, M. Fulcheri, R. Galzio, and Y.B. Shaik-Dasthagirisaheb Cholesterol, cytokines and diseases Int J Immunopathol Pharmacol 24 2011 567 581
15. A. Andrews, E. Balciunaite, F.L. Leong, M. Tallquist, P. Soriano, M. Refojo, and A. Kazlauskas Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy Invest Ophthalmol Vis Sci 40 1999 2683 2689
16. S. Banerjee, V. Savant, R.A. Scott, S.J. Curnow, G.R. Wallace, and P.I. Murray Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders Invest Ophthalmol Vis Sci 48 2007 2203 2207
17. C. Baudouin, D. Fredj-Reygrobellet, F. Brignole, F. Negre, P. Lapalus, and P. Gastaud Growth factors in vitreous and subretinal fluid cells from patients with proliferative vitreoretinopathy Ophthalmic Res 25 1993 52 59
18. H. Canataroglu, I. Varinli, A.A. Ozcan, A. Canataroglu, F. Doran, and S. Varinli Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy Ocul Immunol Inflamm 13 2005 375 381
19. D.G. Charteris Growth factors in proliferative vitreoretinopathy Br J Ophthalmol 82 1998 106
20. M. Citirik, E.U. Kabatas, C. Batman, K.O. Akin, and N. Kabatas Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy Ophthalmic Res 47 2012 7 12
21. J.Z. Cui, A. Chiu, D. Maberley, P. Ma, A. Samad, and J.A. Matsubara Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy Eye (Lond) 21 2007 200 208
22. S.G. Elner, V.M. Elner, G.J. Jaffe, A. Stuart, S.L. Kunkel, and R.M. Strieter Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy Curr Eye Res 14 1995 1045 1053
23. C. Harada, Y. Mitamura, and T. Harada The role of cytokines and trophic factors in epiretinal membranes: involvement of signal transduction in glial cells Prog Retin Eye Res 25 2006 149 164
24. D.R. Hinton, S. He, M.L. Jin, E. Barron, and S.J. Ryan Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy Eye (Lond) 16 2002 422 428
25. I.K. Kim, and J.G. Arroyo Mechanisms in proliferative vitreoretinopathy Ophthalmol Clin North Am 15 2002 81 86
26. C.H. Kon, N.L. Occleston, G.W. Aylward, and P.T. Khaw Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study Invest Ophthalmol Vis Sci 40 1999 705 712
27. E.C. La Heij, M.P. van de Waarenburg, H.G. Blaauwgeers, A.G. Kessels, A.T. Liem, C. Theunissen, H. Steinbusch, and F. Hendrikse Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy Am J Ophthalmol 134 2002 367 375
28. H. Lei, M.A. Rheaume, and A. Kazlauskas Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy Exp Eye Res 90 2010 376 381
29. S. Pennock, M.A. Rheaume, S. Mukai, and A. Kazlauskas A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy Am J Pathol 179 2011 2931 2940
30. R.N. Agrawal, S. He, C. Spee, J.Z. Cui, S.J. Ryan, and D.R. Hinton In vivo models of proliferative vitreoretinopathy Nat Protoc 2 2007 67 77
31. J. Cui, H. Lei, A. Samad, S. Basavanthappa, D. Maberley, J. Matsubara, and A. Kazlauskas PDGF receptors are activated in human epiretinal membranes Exp Eye Res 88 2009 438 444
32. Y. Ikuno, and A. Kazlauskas An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor Invest Ophthalmol Vis Sci 43 2002 2406 2411
33. Y. Ikuno, F.L. Leong, and A. Kazlauskas Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor Invest Ophthalmol Vis Sci 41 2000 3107 3116
34. Y. Zheng, Y. Ikuno, M. Ohj, S. Kusaka, R. Jiang, O. Cekic, M. Sawa, and Y. Tano Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy Jpn J Ophthalmol 47 2003 158 165
35. H. Lei, and A. Kazlauskas Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells J Biol Chem 284 2009 6329 6336
36. H. Lei, G. Velez, P. Hovland, T. Hirose, D. Gilbertson, and A. Kazlauskas Growth factors outside the PDGF family drive experimental PVR Invest Ophthalmol Vis Sci 50 2009 3394 3403
37. S. Pennock, and A. Kazlauskas Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses Mol Cell Biol 32 2012 1955 1966
38. H. Lei, M.A. Rheaume, J. Cui, S. Mukai, D. Maberley, A. Samad, J. Matsubara, and A. Kazlauskas A novel function of p53: a gatekeeper of retinal detachment Am J Pathol 181 2012 866 874
39. H. Lei, G. Velez, and A. Kazlauskas Pathological signaling via platelet-derived growth factor receptor {alpha} involves chronic activation of Akt and suppression of p53 Mol Cell Biol 31 2011 1788 1799
40. S.C. Dieudonne, E.C. La Heij, R.M. Diederen, A.G. Kessels, A.T. Liem, A. Kijlstra, and F. Hendrikse Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy Ophthalmic Res 39 2007 148 154
41. H. Lei, P. Hovland, G. Velez, A. Haran, D. Gilbertson, T. Hirose, and A. Kazlauskas A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy Invest Ophthalmol Vis Sci 48 2007 2335 2342
42. S.G. Robbins, R.N. Mixon, D.J. Wilson, C.E. Hart, J.E. Robertson, I. Westra, S.R. Planck, and J.T. Rosenbaum Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases Invest Ophthalmol Vis Sci 35 1994 3649 3663
43. H. Lei, G. Velez, J. Cui, A. Samad, D. Maberley, J. Matsubara, and A. Kazlauskas N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy Am J Pathol 177 2010 132 140
44. R.A. Klinghoffer, B. Duckworth, M. Valius, L. Cantley, and A. Kazlauskas Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity Mol Cell Biol 16 1996 5905 5914
45. M. Nakagawa, M.F. Refojo, J.F. Marin, M. Doi, and F.I. Tolentino Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy Invest Ophthalmol Vis Sci 36 1995 2388 2395
46. S. Rosenkranz, K.A. DeMali, J.A. Gelderloos, C. Bazenet, and A. Kazlauskas Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis J Biol Chem 274 1999 28335 28343
47. C.A. Wong, M.J. Potter, J.Z. Cui, T.S. Chang, P. Ma, A.L. Maberley, W.H. Ross, V.A. White, A. Samad, W. Jia, D. Hornan, and J.A. Matsubara Induction of proliferative vitreoretinopathy by a unique line of human retinal pigment epithelial cells Can J Ophthalmol 37 2002 211 220
48. J. Waltenberger, L. Claesson-Welsh, A. Siegbahn, M. Shibuya, and C.H. Heldin Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor J Biol Chem 269 1994 26988 26995
49. F. Grinnell, C.H. Ho, Y.C. Lin, and G. Skuta Differences in the regulation of fibroblast contraction of floating versus stressed collagen matrices J Biol Chem 274 1999 918 923
50. D.M. Fastenberg, K.R. Diddie, N. Sorgente, and S.J. Ryan A comparison of different cellular inocula in an experimental model of massive periretinal proliferation Am J Ophthalmol 93 1982 559 564
51. D. Maberley, J.Z. Cui, and J.A. Matsubara Vitreous leptin levels in retinal disease Eye (Lond) 20 2006 801 804
52. P.J. Rosenfeld, D.M. Brown, J.S. Heier, D.S. Boyer, P.K. Kaiser, C.Y. Chung, and R.Y. Kim Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
53. P.J. Rosenfeld, J.S. Heier, G. Hantsbarger, and N. Shams Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration Ophthalmology 113 2006 623.e1
54. C.H. Heldin, and B. Westermark Platelet-derived growth factor: mechanism of action and possible in vivo function Cell Regul 1 1990 555 566
55. R. Ross, D.F. Bowen-Pope, and E.W. Raines Platelet-derived growth factor and its role in health and disease Philos Trans R Soc Lond B Biol Sci 327 1990 155 169
56. E.W. Raines, and R. Ross Purification of human platelet-derived growth factor Methods Enzymol 109 1985 749 773
57. I.A. El-Ghrably, H.S. Dua, G.M. Orr, D. Fischer, and P.J. Tighe Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy Br J Ophthalmol 85 2001 461 470
58. Azzolini CPI, Pirrone C, Moriondo A, Donati S, Chiaravalli AM, Borroni D, Pasquali F, Porta G: Otx2 and VegfA Expression and P53-Otx1 Differentiation Pathway in Proliferative Vitreoretinopathy. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, 2012 May 6-12, Fort Lauderdale, FL
59. Pastor-Idoate S, Rojas J, Rodriguez-Hernández I, Gonzalez-Sarmiento R, Pastor J: Distribution of p53 Codon 72 Polymorphism in European Patients with Proliferative Vitreoretinopathy (PVR). Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, 2012 May 6-12, Fort Lauderdale, FL
60. P. Charbel Issa, R.P. Finger, F.G. Holz, and H.P. Scholl Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia Br J Ophthalmol 92 2008 941 945
61. R.L. Avery, D.J. Pieramici, M.D. Rabena, A.A. Castellarin, M.A. Nasir, and M.J. Giust Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 2006 363 372.e5
62. J.H. Yeo, J. Sadeghi, P.A. Campochiaro, W.R. Green, and B.M. Glaser Intravitreous fibronectin and platelet-derived growth factor: new model for traction retinal detachment Arch Ophthalmol 104 1986 417 421